Onco BCG Injection (40mg) is a therapeutic agent derived from the Bacillus Calmette-Guerin (BCG) strain, primarily used in the treatment of superficial bladder cancer. This immunotherapy works by stimulating the immune system to attack cancer cells, making it a vital option for patients diagnosed with this condition. The composition of Onco BCG Injection includes a live attenuated strain of Mycobacterium bovis, which has been modified to reduce its virulence while retaining its ability to provoke an immune response. This injection is administered directly into the bladder, where it acts locally to elicit a robust immune reaction against tumor cells. Onco BCG is recognized for its effectiveness in reducing tumor recurrence and progression, thus playing a crucial role in bladder cancer management. Its unique mechanism of action and composition make it a cornerstone in the field of oncology, particularly for patients seeking alternatives to more invasive treatments.